Reserve Bank of Australia Assistant Governor (Economic) Sarah Hunter said higher interest rates are already slowing parts of the economy, particularly housing, but the Bank continues to see inflation risks skewed to the upside. Speaking Read more…
Boston Fed President Susan Collins said she supported last week’s 25bp rate hike and expects one additional increase later this year, citing disappointing inflation progress and renewed energy risks from the Middle East conflict. Collins Read more…
St. Louis Fed President Alberto Musalem said further policy restraint will likely be needed because inflation is being sustained by both strong domestic demand and recurring supply shocks, with pressure now extending beyond oil. In Read more…
Bank of Canada Governor Tiff Macklem said the Bank can continue to “look through” the direct inflation impact of higher oil prices only while those pressures remain contained, drawing a clearer line around when the Read more…
Hello fellow traders. In this technical blog we’re going to take a quick look at the Elliott Wave charts of OIL (CL_F) published in members area of the website. As our members know, OIL is Read more…
Every crypto winter, the sentiment for Bitcoin turns bearish and one question keeps resurfacing among the circles of critics and investors: can Bitcoin go to zero? This is despite the price of the flagship cryptocurrency Read more…
S&P 500 Index: ⬆️ Buy – S&P 500 Index reversed from support zone – Likely to rise to resistance level 7820.00 S&P 500 Index recently reversed up from the support zone between the 50% Fibonacci Read more…
Platinum: ⬆️ Buy – Platinum reversed from support zone – Likely to rise to resistance level 1900.00 Platinum recently reversed up from the support zone between the lower daily Bollinger Band, 50% Fibonacci correction of Read more…
China A50 Index: ⬆️ Buy – China A50 Index reversed from support zone – Likely to rise to resistance level 14800.00 China A50 index recently reversed up from the support zone located between the key Read more…
Amgen’s (AMGN) closely watched cardiovascular drug candidate lost a major rival on Sept. 4, when Novartis (NVS) announced that its pelacarsen trial failed to reduce heart attacks and strokes in high-risk patients. The surprising part Read more…